PBT434 inhibits alpha- synuclein in the brain., page-3

First 3 Last

Share
Profile

Follow
skint

5,897 Posts.

151

03/08/19

05:24

Post #: 39841396
Share

Originally posted by pivalde: ↑

skint, this is an important statement by ATH and looks to be based on the Finkelstein paper and the MSA mouse study but not to phase 1 study (???).
The other day we got this report (below) how CSF alpha-synuclein is not so good in monitoring the progress in PD. It is not a free paper so I made my conclusions only by the abstract. IMO the paper does not contradict the statement by ATH but I think that it is worth posting. Brain alpha-synuclein is important, not CSF alpha-synuclein.

Mov Disord. 2019 Jul 30. doi: 10.1002/mds.27806. [Epub ahead of print]
Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease.
Mollenhauer B¹, Caspell-Garcia CJ², Coffey CS², Taylor P³, Singleton A⁴, Shaw LM⁵, Trojanowski JQ^6,⁷, Frasier M⁸, Simuni T⁹, Iranzo A¹⁰, Oertel W¹¹, Siderowf A^7,¹², Weintraub D¹², Seibyl J¹³, Toga AW¹⁴, Tanner CM¹⁵, Kieburtz K¹⁶, Chahine LM¹⁷, Marek K¹³, Galasko D¹⁸; PPMI study.
Author information

Abstract
BACKGROUND:
Aggregation of α-synuclein is central to the pathophysiology of PD. Biomarkers related to α-synuclein may be informative for PD diagnosis/progression.
OBJECTIVES:
To analyze α-synuclein in CSF in drug-naïve PD, healthy controls, and prodromal PD in the Parkinson's Progression Markers Initiative.
METHODS:
Over up to 36-month follow-up, CSF total α-synuclein and its association with MDS-UPDRS motor scores, cognitive assessments, and dopamine transporter imaging were assessed.
RESULTS:
The inception cohort included PD (n = 376; age [mean {standard deviation} years]: 61.7 [9.62]), healthy controls (n = 173; age, 60.9 [11.3]), hyposmics (n = 16; age, 68.3 [6.15]), and idiopathic rapid eye movement sleep behavior disorder (n = 32; age, 69.3 [4.83]). Baseline CSF α-synuclein was lower in manifest and prodromal PD versus healthy controls. Longitudinal α-synuclein decreased significantly in PD at 24 and 36 months, did not change in prodromal PD over 12 months, and trended toward an increase in healthy controls. The decrease in PD was not shown when CSF samples with high hemoglobin concentration were removed from the analysis. CSF α-synuclein changes did not correlate with longitudinal MDS-UPDRS motor scores or dopamine transporter scan.
CONCLUSIONS:
CSF α-synuclein decreases early in the disease, preceding motor PD. CSF α-synuclein does not correlate with progression and therefore does not reflect ongoing dopaminergic neurodegeneration. Decreased CSF α-synuclein may be an indirect index of changes in the balance between α-synuclein secretion, solubility, or aggregation in the brain, reflecting its overall turnover. Additional biomarkers more directly related to α-synuclein pathophysiology and disease progression and other markers to be identified by, for example, proteomics and metabolomics are needed. © 2019 International Parkinson and Movement Disorder Society.

Expand

Pivalde it is based on the human trial. Look at the last announcement on their site.

ATH Price at posting: 2.6¢ Sentiment: None Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

The Rising Tide: How institutional adoption is shaping the future of crypto

Why are so many ASX explorers setting up shop in Saudi Arabia? + 8 stocks to watch

CC9

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

SER

How flooding did Strategic Energy Resources a favour: Four holes down in 'redesigned' gold & copper campaign

FXG

What on earth is antimony – and why are ASX traders going crazy for it? + 6 stocks to watch

There are more pages in this discussion • 25 more messages in this thread...

First 3 Last

Add ATH (ASX) to my watchlist

(20min delay)
Last 0.4¢		Change 0.000(0.00%)		Mkt cap ! $21.28M

Open	High	Low	Value	Volume
0.4¢	0.4¢	0.4¢	$5.012K	1.294M

Buyers (Bids)

No.	Vol.	Price($)
43	54662006	0.3¢

Sellers (Offers)

Price($)	Vol.	No.
0.4¢	126993867	29

View Market Depth

No.	Vol.	Price($)
43	54662006	0.003
56	84698098	0.002
25	120860100	0.001
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.004	126993867	29
0.005	29734782	29
0.006	13206477	19
0.007	47601651	22
0.008	22833132	23

Last trade - 16.10pm 28/08/2024 (20 minute delay)

ATH (ASX) Chart

PBT434 inhibits alpha- synuclein in the brain., page-3

The Rising Tide: How institutional adoption is shaping the future of crypto

Why are so many ASX explorers setting up shop in Saudi Arabia? + 8 stocks to watch

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

How flooding did Strategic Energy Resources a favour: Four holes down in 'redesigned' gold & copper campaign

What on earth is antimony – and why are ASX traders going crazy for it? + 6 stocks to watch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

PBT434 inhibits alpha- synuclein in the brain., page-3

Top Stories

The Rising Tide: How institutional adoption is shaping the future of crypto

Why are so many ASX explorers setting up shop in Saudi Arabia? + 8 stocks to watch

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

How flooding did Strategic Energy Resources a favour: Four holes down in 'redesigned' gold & copper campaign

What on earth is antimony – and why are ASX traders going crazy for it? + 6 stocks to watch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News